Publication: Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis.
| dc.contributor.author | Virseda-Berdices, Ana | |
| dc.contributor.author | Requena, Belen | |
| dc.contributor.author | Berenguer, Juan | |
| dc.contributor.author | Gónzalez-García, Juan | |
| dc.contributor.author | Gonzalez-Riano, Carolina | |
| dc.contributor.author | Díez, Cristina | |
| dc.contributor.author | Hontañón, Victor | |
| dc.contributor.author | Muñoz-García, Paula | |
| dc.contributor.author | Fernandez-Rodriguez, Amanda | |
| dc.contributor.author | Barbas, Coral | |
| dc.contributor.author | Resino, Salvador | |
| dc.contributor.author | Martín-Escolano, Rubén | |
| dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
| dc.contributor.author | the Marathon Study Group | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) | |
| dc.contributor.funder | Unión Europea. Comisión Europea. NextGenerationEU | |
| dc.contributor.funder | Comunidad de Madrid (España) | |
| dc.date.accessioned | 2026-03-25T11:57:37Z | |
| dc.date.available | 2026-03-25T11:57:37Z | |
| dc.date.issued | 2025-12 | |
| dc.description.abstract | Background: Despite successful hepatitis C virus (HCV) clearance, some individuals continue to experience liver disease progression. Metabolic dysfunction-associated steatotic liver disease (MASLD) may play a key role in this ongoing progression. This study aims to characterize the lipidomic profiles associated with MASLD in individuals coinfected with human immunodeficiency virus (HIV) and HCV with advanced fibrosis or cirrhosis after sustained virologic response (SVR). Methods: We conducted cross-sectional studies in fifty-two HIV/HCV-coinfected individuals. Untargeted lipidomics was performed on plasma samples collected at 1 year and 6 years post-SVR using liquid chromatography-mass spectrometry. The primary outcome was MASLD. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA) and generalized linear models (GLM), with corrections for multiple comparisons. Results: The prevalence of MASLD was 28.9 % one year after SVR, increasing to 44.8 % six years after SVR. OPLS-DA models identified 225 lipids at 1 year and 167 at 6 years, with a VIP score ≥ 1, distinguishing individuals based on MASLD status. Adjusted GLMs confirmed significant associations between MASLD and 116 lipids at 1 year and 49 at 6 years. At 1 year, most significant lipids were glycerophospholipids (GP), with increased phosphatidylcholines (PC) and phosphatidylethanolamines (PE), and decreased lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE). By 6 years, LPC was the most abundant differential lipid, while triglycerides increased significantly. Conclusions: MASLD was common during follow-up, with changes in lipidomic profiles over time suggesting ongoing metabolic disturbances that may contribute to liver disease progression despite SVR. These findings highlight the need for long-term metabolic and liver health monitoring after HCV eradication in these individuals. | |
| dc.description.peerreviewed | Sí | |
| dc.description.sponsorship | This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI21CIII/00033 to MAJS, PI24CIII/00003 to SR, and PI24CIII/00003 to RME). The study was also funded by the CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU (CB21/13/00044). RME is César Nombela researcher supported and funded by Comunidad de Madrid (grant number 2023-T1/SAL-GL-28980). | |
| dc.format.number | 12 | |
| dc.format.page | 102981 | |
| dc.format.volume | 18 | |
| dc.identifier.citation | Virseda-Berdices A, Requena B, Berenguer J, Gónzalez-García J, Gonzalez-Riano C, Díez C, Hontañón V, Muñoz-García P, Fernández-Rodríguez A, Barbas C, Resino S, Martín-Escolano R, Jiménez-Sousa MÁ; Marathon Study Group. Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis. J Infect Public Health. 2025 Dec;18(12):102981. doi: 10.1016/j.jiph.2025.102981. Epub 2025 Sep 27. PMID: 41033169. | |
| dc.identifier.doi | 10.1016/j.jiph.2025.102981 | |
| dc.identifier.journal | Journal of Infection and Public Health | |
| dc.identifier.pubmedID | 41033169 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/27348 | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Proyectos de I+D+I en salud (AESI 2024)/PI24CIII%2F00003//Biomarcadores plasmáticos de envejecimiento y esteatohepatitis no alcohólica en personas que viven con VIH: un estudio de asociación con aleatorización mendeliana/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud Intramurales/PI21CIII%2F00033//Análisis multi-ómico para evaluar el impacto a largo plazo de la erradicación del VHC en pacientes coinfectados por VIH/VHC con cirrosis/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/Comunidad de Madrid/2023-T1%2FSAL-GL-28980/// | |
| dc.relation.publisherversion | https://doi.org/10.1016/j.jiph.2025.102981 | |
| dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología (CNM) | |
| dc.repisalud.institucion | ISCIII | |
| dc.rights.accessRights | open access | |
| dc.rights.license | Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | HCV eradication | |
| dc.subject | Lipidomics | |
| dc.subject | MASLD | |
| dc.subject | PWH | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Antiviral Agents | |
| dc.subject.mesh | Coinfection | |
| dc.subject.mesh | Cross-Sectional Studies | |
| dc.subject.mesh | Disease Progression | |
| dc.subject.mesh | Fatty Liver | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | HIV Infections | |
| dc.subject.mesh | Hepatitis C | |
| dc.subject.mesh | Hepatitis C, Chronic | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Lipidomics | |
| dc.subject.mesh | Lipids | |
| dc.subject.mesh | Liver Cirrhosis | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Sustained Virologic Response | |
| dc.title | Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | d18c653c-226a-4a2f-9a10-e2b5af9c3b33 | |
| relation.isAuthorOfPublication | 6a32a4a3-2d81-43c5-8295-48346efbf498 | |
| relation.isAuthorOfPublication | 89b17350-14e3-4dfd-b797-6ee6ca5363b8 | |
| relation.isAuthorOfPublication | 32640c9c-427d-403a-9a9d-bc40351fb486 | |
| relation.isAuthorOfPublication | 2bf7faec-7f00-44ba-9494-efb396305551 | |
| relation.isAuthorOfPublication.latestForDiscovery | d18c653c-226a-4a2f-9a10-e2b5af9c3b33 | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | 0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72 | |
| relation.isFunderOfPublication | 54f29c6e-1163-4239-8d1d-a0f297ca06e6 | |
| relation.isFunderOfPublication | c87c70a3-e023-4b6b-ac25-1b2d1b483786 | |
| relation.isFunderOfPublication.latestForDiscovery | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isPublisherOfPublication | 7d471502-7bd5-4f7a-90a4-8274382509ef | |
| relation.isPublisherOfPublication.latestForDiscovery | 7d471502-7bd5-4f7a-90a4-8274382509ef |


